Payment overview · 2025
General Payments
$363.95
21 reported records · 13 companies
Healthcare provider profile · identity verified
David C Napier, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FRANKLIN, KY · NPI 1083639272
Verified facts
What the public records show
CMS Open Payments records show David C Napier, M.D. received $363.95 in general payments during 2025 across 21 reported records.
Novo Nordisk Inc accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic, Rybelsus, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SEROQUEL as an associated drug or biological on 59 records involving 53 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Seroquel by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $80.55 | 22.1% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $61.90 | 17.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $59.02 | 16.2% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$20.11 | 5.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.03 | 5.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.85 | 5.5% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $18.33 | 5.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.19 | 5.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.18 | 4.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.03 | 4.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.96 | 4.1% | 1 | 2025 |
| Vital Connect, Inc | Unresolved — no canonical attribution shown | $14.23 | 3.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $4.57 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $363.95 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $61.90 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $59.02 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $59.02 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.74 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.74 | 3 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $20.11 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| VITALPATCH RTM Normalized: vitalpatch rtm |
Device | Vital Connect, Inc | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $4.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 193 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 189 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
98 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SEROQUEL open payments reported associated product |
CMS Open Payments — General Payments 59 supporting records · 53 recipient NPIs · example record 1241586771 |
Seroquel · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
189 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
193 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 995 | 224 |
| Metoprolol Succinate | Metoprolol Succinate | 663 | 129 |
| Losartan Potassium | Losartan Potassium | 653 | 135 |
| Amlodipine Besylate | Amlodipine Besylate | 605 | 133 |
| Pantoprazole Sodium | Pantoprazole Sodium | 514 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 491 | 99 |
| Gabapentin | Gabapentin | 373 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 322 | 70 |
| Lisinopril | Lisinopril | 317 | 60 |
| Furosemide | Furosemide | 306 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 263 | 54 |
| Metformin Hcl | Metformin Hcl | 258 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 240 | 85 |
| Sertraline Hcl | Sertraline Hcl | 232 | 44 |
| Montelukast Sodium | Montelukast Sodium | 228 | 50 |
| Famotidine | Famotidine | 226 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 214 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 211 | 52 |
| Fluoxetine Hcl | Fluoxetine Hcl | 199 | 35 |
| Eliquis | Apixaban | 193 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 193 | 43 |
| Ozempic | Semaglutide | 189 | 32 |
| Metformin Hcl Er | Metformin Hcl | 185 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 182 | 82 |
| Celecoxib | Celecoxib | 169 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 156 | 41 |
| Bupropion Xl | Bupropion Hcl | 151 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 150 | 25 |
| Finasteride | Finasteride | 148 | 33 |
| Carvedilol | Carvedilol | 131 | 25 |
| Omeprazole | Omeprazole | 126 | 34 |
| Prednisone | Prednisone | 126 | 63 |
| Allopurinol | Allopurinol | 124 | 28 |
| Simvastatin | Simvastatin | 120 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 119 | 28 |
| Potassium Chloride | Potassium Chloride | 119 | 27 |
| Mirtazapine | Mirtazapine | 117 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 109 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 106 | 23 |
| Synthroid | Levothyroxine Sodium | 98 | 18 |
| Buspirone Hcl | Buspirone Hcl | 91 | 19 |
| Pregabalin | Pregabalin | 86 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 86 | 14 |
| Tramadol Hcl | Tramadol Hcl | 85 | 19 |
| Meloxicam | Meloxicam | 84 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 83 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 81 | 16 |
| Spironolactone | Spironolactone | 81 | 18 |
| Benazepril Hcl | Benazepril Hcl | 80 | 14 |
| Terazosin Hcl | Terazosin Hcl | 71 | 16 |
| Methocarbamol | Methocarbamol | 68 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 11 |
| Donepezil Hcl | Donepezil Hcl | 54 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 54 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 13 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 52 | 13 |
| Jardiance | Empagliflozin | 52 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 15 |
| Aripiprazole | Aripiprazole | 46 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 43 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 25 |
| Ondansetron Odt | Ondansetron | 41 | 16 |
| Azithromycin | Azithromycin | 40 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 17 |
| Meclizine Hcl | Meclizine Hcl | 40 | 15 |
| Trazodone Hcl | Trazodone Hcl | 40 | 12 |
| Diazepam | Diazepam | 39 | 14 |
| Ramipril | Ramipril | 39 | suppressed |
| Chlorthalidone | Chlorthalidone | 38 | 12 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Lansoprazole | Lansoprazole | 36 | suppressed |
| Nitroglycerin | Nitroglycerin | 35 | 19 |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 24 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 34 | 31 |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | suppressed |
| Brilinta | Ticagrelor | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Lorazepam | Lorazepam | 33 | 12 |
| Atenolol | Atenolol | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | 12 |
| Tradjenta | Linagliptin | 30 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 25 | suppressed |
| Seroquel | Quetiapine Fumarate | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 22 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 21 | suppressed |
| Cefdinir | Cefdinir | 21 | 19 |
| Mupirocin | Mupirocin | 21 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 12 |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Minoxidil | Minoxidil | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $363.95 · 21 records | Novo Nordisk Inc | Auvelity, ELIQUIS, FARXIGA, INSPIRE, Kerendia, MINIMED 780G, NURTEC ODT, OTEZLA, Omnipod, Ozempic, QULIPTA, REPATHA, Rybelsus, SHINGRIX, UBRELVY, VITALPATCH RTM, VOQUEZNA, Wegovy | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error